Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro® unlocks Structural Insights into Key Metabolic Transporter SLC33A1
2025-04-25
Great science enabled by Salipro®: A new study published in Cell Discovery, details the cryo-EM structure of the human acetyl-CoA transporter SLC33A1, offering mechanistic insights crucial for targeting diseases like neurodegeneration and cancer.
Understanding how SLC33A1 recognizes and transports its substrate is vital for developing novel therapeutics. With the Salipro® platform, the authors successfully stabilized human SLC33A1, enabling researchers to determine its 3.5 Å cryo-EM structure complexed with acetyl-CoA.
Key implications of this research:
Advances fundamental understanding of SLC33A1's vital physiological functions.
Provides a structural blueprint with significant potential to guide drug development for conditions including neurodegenerative disorders, aging-related diseases, and certain cancers.
Read the full article here: D. Zhou, et al., Mechanistic insights into the acetyl-CoA recognition by SLC33A1. Cell Discov. 11, 36 (2025).
Salipro Biotech at PEGS Boston, May 12-16!
2025-04-23
Salipro Biotech will be in PEGS Boston, taking place on May 12-16, ready to connect!
Our Business Development Director, Peter Jahnmatz, will present a poster highlighting the latest advancements on the Salipro® platform for the stabilization of challenging membrane protein targets for drug discovery applications.
If you are attending PEGS Boston, make sure to stop by Peter's poster to say hi and discover how the Salipro® technology can accelerate your pipeline programs targeting difficult membrane proteins such as GPCRs, ion channels and SLC transporters.
We look forward to connecting with fellow researchers and industry leaders at PEGS Boston!
For more information on PEGS Boston, please visit the website: https://www.pegsummit.com
Salipro Biotech speaker at Bio Korea 2025
2025-04-15
Salipro Biotech is heading to Bio Korea 2025, taking place from May 7-9 at COEX, Seoul, as part of the Swedish Life Science Delegation.
Don't miss Lorena's presentation at the Global BIO Connection (Country Day session) on Thursday, May 8 at 12:15. She will present Salipro Biotech and showcase the recent developments on the Salipro® technology to advance drug discovery against membrane protein drug targets.
You can also find us at the Swedish Pavilion booth, where our Business Development Manager, Lorena Galán-Acosta, will be available to explore potential collaborations opportunities.
Would you like to connect? Feel free to book a meeting via the Partnering Center : https://www.biokorea.org/program/partneringCenterParticipant.asp
We look forward to meeting you in Seoul!
More information on the conference here: https://www.biokorea.org/index.asp